Ovarian cancer is not often diagnosed until it has progressed to the latter stages of disease, consequently resulting in a 5-year survival rate of <50%. Recurrent ovarian cancer is typically resistant to a wide range of chemotherapy and therefore the investigation of different chemotherapeutic agents in clinical trials is of fundamental significance in trying to establish appropriate treatment for recurrent ovarian cancer.
In this research article, T. Le et al. evaluated the toxicological effects and response rate of gemcitabine/cisplatin verses gemcitabine/carboplatin for the treatment of both platinum-sensitive and platinum-resistant recurrent ovarian cancer.
Click here to access the full article.